
Astrazeneca’s medication combination performs well in a cancer trial.
In a late-stage experiment including patients with advanced or recurrent endometrial cancer, Imfinzi and Lynparza from AstraZeneca showed promising outcomes when combined with platinum-based chemotherapy.